Trials / Completed
CompletedNCT03054350
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Akebia Therapeutics · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Dialysis-dependent Chronic Kidney Disease (DD-CKD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vadadustat | Daily oral dose |
| DRUG | Placebo | Daily oral dose |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-10-24
- Completion
- 2018-01-24
- First posted
- 2017-02-15
- Last updated
- 2021-04-08
- Results posted
- 2021-04-08
Locations
18 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03054350. Inclusion in this directory is not an endorsement.